Evaluation of the Performance of the Associates of Cape Cod STAT Assay for the Diagnosis of Invasive Fungal Disease in Critical-Care Patients with COVID-19

Abstract

During the COVID-19 pandemic, there have been increasing reports of invasive fungal disease (IFD) in critical care, where rapid access to (1-3)-β- d -glucan (BDG) testing may have enhanced diagnosis. The potential benefit of rapidly accessible BDG results is limited by local availability of BDG testing, with low demand resulting in testing being performed in specialist centers.